Intesa invests 360 million euros to manage its entire health insurance business

Published Date: 08 Mar 2023

Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.

Read Full News

Latest News

How the Affordability Crisis Is Hitting PAs

Rising costs are squeezing physician associates just like everyone else. How they’re reshaping their finances, career choices, and quality of life.

Bristol Myers Ends Blood Cancer Drug Deal With Cell Therapy Maker Cellares

Bristol Myers Squibb has ended its partnership with cell therapy startup Cellares to expand the ⁠manufacturing of its personalized blood cancer therapy, a company...

Eli Lilly Launches Oral Weight-loss Drug Foundayo in UK

Eli Lilly has launched its pill, Foundayo, in the UK for weight management and type 2 diabetes, it said on Monday, ⁠making Britain the first country in Europe where the oral...

Nurses Speak Out on Burnout, Mandatory Overtime, and Burning the Candle at Both Ends

Emotionally drained, sleep-deprived, and skipping meals to keep up: what nurse leaders say needs to change to prevent burnout.

Most Family Physicians Struggle With After-Hours Admin Work

Most family physicians face heavy administrative burden, but improved electronic health records and staff support may help to ease some of the load.

Lawsuit Against Bristol Myers Over Delayed Cancer Drug Is Revived

A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former ⁠Celgene shareholders by delaying...

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Latest News

Rising costs are squeezing physician associates just like everyone else. How they’re reshaping their finances, career choices, and quality of life.

Bristol Myers Squibb has ended its partnership with cell therapy startup Cellares to expand the ⁠manufacturing of its personalized blood cancer therapy, a company...

Eli Lilly has launched its pill, Foundayo, in the UK for weight management and type 2 diabetes, it said on Monday, ⁠making Britain the first country in Europe where the oral...

Emotionally drained, sleep-deprived, and skipping meals to keep up: what nurse leaders say needs to change to prevent burnout.

Most family physicians face heavy administrative burden, but improved electronic health records and staff support may help to ease some of the load.

A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former ⁠Celgene shareholders by delaying...

News All Time

Trump Cuts New York Funding for Medicaid Fraud Unit

The Trump administration said on Tuesday it would cut off funding to ⁠New York's Medicaid fraud unit, accusing it of underperforming in a move that could jeopardize the...

Europe Must Rethink Medicine Pricing or Risk Losing Investment

Europe will need to rethink how it values and pays for innovative ⁠medicines or risk losing manufacturing investments and clinical trials, the head of Europe's pharmaceutical industry lobby said.

Medicare AI Creates Errors and Delays for Patients, Doctors

Patients, doctors, and other healthcare professionals who spoke with KFF Health News say the effort has created confusion, errors, long wait times, and stress.

Analysis-Big Pharma Taps UK Playbook to Pressure European Capitals on Drug Prices

Global pharmaceutical companies, facing pushback from European capitals on drug pricing, are turning to a playbook that brought them recent success in Britain: threats of...

Studies Confirm Private Equity Dangers

A handful of studies confirm that hospitals taken over by private equity have worse outcomes for patients.

Cholera Outbreak in Nigeria's Borno Kills 74, Infects Thousands Since May

A cholera outbreak that began in early May in Nigeria's northeastern Borno state ⁠has killed at least 74 people and infected more than 7,800, overwhelming health facilities,...

Nurses Filling Doctor Gaps: What Happens to Hard Cases?

As health systems consider shifting more physician tasks to nurses, Medscape readers focused on whether expanded care models include clear supervision, escalation, and time for patients who do not fit routine protocols.

FDA Grants Emergency Approval for Over-the-counter Drug to Treat Screwworm in Pets

The U.S. Food and Drug Administration on Thursday authorized the emergency use of a generic over-the-counter tablet ⁠to treat infestations caused by the New World screwworm...

More Nurses are Clocking in to Second Jobs

More nurses regularly take on second shifts but as the practice becomes normalized, is this best for patients?

Sandoz Files European Complaint About Chinese Antibiotic Imports

Swiss generic drugmaker Sandoz filed a draft ⁠anti-dumping complaint with the European Commission over Chinese imports ⁠of the antibiotic ingredient amoxicillin.

What Your ZIP Code Is Costing You

Forget salary. The cities winning the physician satisfaction race are playing a completely different game.

How NPs Are Navigating Prior Authorization Coverage Barriers

The same hurdles facing physicians slow treatment for nurse practitioners’ patients, and the impact on care continues.

US FDA Issues Recall Of Boston Scientific Heart Devices

Boston Scientific has issued an urgent recall to correct several heart devices after ⁠the U.S. Food and Drug Administration classified the action as its most serious recall,...

Delays in Visa Program Threaten Hundreds of Doctors

Prolonged HHS J-1 waiver backlogs leave hundreds of foreign-trained doctors facing departure this summer, threatening care in underserved areas, immigration attorneys warn.

AstraZeneca to Invest $405 Million in Britain After US-UK Pharma Deal

Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 ⁠million) in the country, after pausing...

Europe Risks Falling Behind in Medicine Race, Roche CEO

Europe risks falling behind the US and China in pharma innovation because of bureaucracy and government policies threatening ⁠jobs, Roche CEO Thomas Schinecker warns.

Recommended News For You

Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx

Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.

Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer

How breast tissue density affects your risk of breast cancer

Rectal Cancer 'Crisis'; Smells Like Cancer; Flushing Away Clues to Colon Cancer

A small rise in cancer was observed following the 1986 Chernobyl accident.

An Eye Surgeon's Unexpected Discovery of the "Before and After".

Recommended Articles For You

The Surprising Role of Magnesium in Digestion, Sleep and Mental Health  

Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis 

A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures 

Tumor Microenvironment Readiness as a Predictor of Cancer Progression 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study

2.

New methods show how fast breast cancers grow and how surgery delays affect cancer staging

3.

Some low-grade prostate cancers carry higher risks than biopsy suggests

4.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

5.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

1.

Unraveling the Mysteries of Hematocrit: How It Impacts Your Health

2.

Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy

3.

Clinical Pharmacology of Erythroid Maturation Pathway Regulators

4.

Precision Medicine for Bone Marrow Microenvironment Remodeling

5.

Everything You Need to Know About HTLV: A Comprehensive Guide 

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

2.

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

3.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot